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Abstract: A series of Schiff bases derived from 2-acetylpyridne and their metal complexes 
were characterized by elemental analysis, NMR, FT-IR and UV-Vis spectral studies.  
The complexes were screened for anti-bacterial activity against Methicillin-resistant 
Staphylococcus aureus (MRSA), Acinetobacter baumanni (AC), Klebsiella pneumonie 
(KB) and Pseudomonas aeruginosa (PA) using the disc diffusion and micro broth dilution 
assays. Based on the overall results, the complexes showed the highest activities against 
MRSA while a weak antibacterial activity was observed against A. baumanii and  
P. aeruginosa. 
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1. Introduction 
Schiff base ligands containing various donor atoms (like N, O, S, etc.) show broad biological 
activities and are of special interest due to variety of ways in which they can bond to metal ions. It is 
known that the existence of metal ions bonded to biologically active compounds may enhance their 
activities [1]. Schiff base metal complexes show great diversity in their varied biological activities as 
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anticonvulsant [2], antifungal [3–7], anti-HIV [8], antiviral and anticancer [9] antimicrobial [10–15] 
and antibacterial [16] agents. 
Nosocomial infections caused by multidrug resistant bacteria are an increasing medical problem 
worldwide, particularly among immunocompromised patients and those hospitalized in intensive care 
units. Both Gram positive and Gram negative bacteria have developed high level resistance to multiple 
classes of antibacterial agents. These include methicillin resistant Staphylococcus aureus (MRSA), 
Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli and vancomycin resistant 
enterococci (VRE) [17]. Few available drugs such as linezolid and some newer glycopeptides, and 
tigecycline are active against MRSA and VRE, but their success rates are variable [18]. As such, there 
is a need to explore other sources of effective antibacterial compounds to augment the limited choice 
of drugs for therapeutic treatment. 
 In this study, transition metal complexes of some newly synthesized N,N′,N′′-donor Schiff base 
ligands obtained from the reaction of 4-(2-aminoethyl)morpholine, 4-(2-aminoethyl)piperazine or  
N,N-dimethylethylenediamine with 2-acetylpyridine in the presence of Cl−, Br−, and SCN− ions were 
examined for potential antimicrobial activities. Most of the synthesized compounds present a morpholine 
derivative which has been used as a building block for preparation of the antibiotic linezolid [19,20]. 
The morpholine ring is important for antimicrobial activity as proved by quantitative structure activity 
relationship (QSAR) [21]. The objective of the study was to determine the anti-bacterial activities  
for the transition metals complexes against methicillin-resistant Staphylococcus aureus (MRSA), 
Acinetobacter baumanni (A. baumanni), Klebsiella Pneumonie (K. pneumonie) and Pseudomonas 
aeruginosa (P. aeruginosa) by using the disc diffusion and micro broth dilution assays.  
2. Results and Discussion 
The reaction of 2-acetylpyridine with 4-(2-aminoethyl)morpholine, 4-(2-aminoethyl)piperazine  
or N,N-dimethylethylenediamine resulted in the formation of corresponding Schiff base ligands;  
2-morpholino-N-(1-(pyridin-2-yl)ethylidene)ethanamine (1), 2-(piperazin-1-yl)-N-(1-(pyridin-2-yl)-
ethylidene)ethanamine (2), N1,N1-dimethyl-N2-(1-(pyridin-2-yl)ethylidene)ethane-1,2-diamine (3). 
The prepared Schiff bases further reacted cadmium(II), copper(II), nickel(II) and zinc(II) ions in the 
presence of Cl−, Br−, SCN− ions giving rise to different coordination complexes (Scheme 1). The 
compounds exhibited NMR, IR and UV-Visible spectra consistent with the proposed structures which 
allowed the synthesized complexes to be recognized as aqua{dithiocyanato-(2-morpholino-N-[1-(2-
pyridylethylidene]ethanamine N,N′,N′′}cadmium(II) (4), aqua{dichloridopiperazin-4-ium1-(2-pyridyl) 
ethylidene]ethanamine N,N′,N′′}cadmium (5), chlorido(2-{1-[(2-morpholinoethyl)imino]ethyl}-
phenolato N,N′,N′′)copper(II) (6), dibromido{2-morpholino-N-[1-(2-pyridyl)ethylidene)ethanamine 
N,N′,N′′}cadmium (7), dibromido{2- N,N′,N′′}bis(thiocyanato) nickel(II) (10), respectively. In this 
context, it would be worthy morpholino-N-[1-(2-pyridyl)ethylidene] ethanamine N,N′,N′′} zinc (8), 
N,N-dimethyl-N’-[1-(2-pyridyl)ethylidene]ethane-1,2-diamine-3N,N′,N′′}bis(thiocyanate) zinc(II) (9), and 
aqua{2-morpholino-N-[1-(2-pyridyl)ethylidene]ethanamine to compare the structures of some earlier 
prepared complexes with the present ones. There are two reported complexes of nickel(II) perchlorate 
with the similar donor-Schiff base ligand [22]. 
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Scheme 1. Reaction pathway for the coordinated complexes. 
 
2.1. Infrared Spectra 
The IR spectra of the compounds were recorded in the 4000–400 cm−1 range. The characteristic IR 
stretching frequencies along with their proposed assignments are summarized in the Experimental 
section. There are similarities in the IR spectra of the ligands and their corresponding metal complexes 
to each other, except for some slight variations in the shifts and intensities caused by different metal(II) 
ions. However, there were some significant differences between the metal(II) halides complexes and 
those of the thiocyanate complexes, as expected. The IR spectra of all the compounds possess very 
strong characteristic absorption bands in the 1,585–1,656 cm−1 region which are attributed to the C=N 
stretching vibration of the Schiff base functional group [11,23,24]. The hydrated complexes (4, 5 and 
10) exhibited an IR band at approximately 650–700 cm−1 range due to ν(H2O), suggesting the 
coordination of water molecules [25,26]. The characteristic sharp and distinct absorption bands for 
N=C=S appear in the 2,030–2,120 cm−1 region for compounds 4, 9 and 10 [27,28]. All complexes 
showed M-N bands at a lower wavelength in the range of 454–556 cm−1 [29–32]. 
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2.2. Electronic Spectra 
The electronic spectra for all the compounds were obtained in DMSO solutions and showed 
absorption bands in three distinct regions. The first region ranging from 200 to approximately 229 nm, 
is characteristic for the electronic inter-ligand π→π* transitions [33], while the second characteristic 
wavelength in the region of 280 nm to approximately 350 nm is the second inter ligand n→π  
transition [34]. The third distinct region ranging from 407 nm to approximately 500 nm is the 
characteristic for the ligand to metal charge transfer (LMCT) from the nitrogen atom to the transition 
metal centre [35]. For the nickel(II) and copper(II) ions, bands were observed between 600 and 750 nm 
which can be attributed to d–d* transitions of the metal ions respectively [36]. 
2.3. 1H- and 13C-NMR-NMR Spectra 
The signals for the aromatic ring protons appear in the region of 7.80–8.80 [37]. While the other 
singlet peaks appeared in the region of 1.80–2.65 ppm which were attributed to CH3 indicating the 
methyl on the carbonyl group [37]. Also in the piperazine compound 5 additional signals was observed 
at 2.30 ppm which was assigned to (NH–). In the 13C-NMR spectra of the metal complexes, the signals 
in the range from 160.00–170.00 ppm were assigned to azomethine carbon atoms (C=N) [32]. 
Aromatic ring carbon atoms were determined in the range of 120.00–150.00 ppm [37]. Additional signals 
were observed at 21.98 ppm and 22.75 ppm, which were assigned to the carbon atom of (NCS) for 
compounds 4 and 9, respectively. 
2.4. X-Ray Crystal and Molecular Structure  
Compound 8 was obtained upon the reaction of 2-morpholino-N-[1-(2-pyridyl)ethylidene]-
ethanamine with Zn(II) ion in the presence of potassium bromide. Similar to the structure of the 
analogous ZnCl2 complex [38], the metal center is five-coordinated by the N,N′,N′′-tridentate Schiff 
base ligand and two halogen atoms (Figure 1).  
Figure 1. The molecular X-ray structure of 8 and 9 showing the atom labeling scheme 
(50% probability ellipsoids). Hydrogen atoms are drawn as spheres of arbitrary radius. 
    
The geometry of the complexes can be determined by using the index τ = (β-α)/60, where β is the 
largest angle and α is the second one around the metal center. For an ideal square-pyramid τ is 0, while 
8 9 
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it is 1 in a perfect trigonal-bipyramid [39]. The τ value in the present structure is calculated to be 0.30, 
indicative of a distorted square-pyramidal geometry. The Zn-Br and Zn-N bond lengths in the complex 
are in agreement with the values reported in the literature [40,41]. The Zn(II) ion in the compound, is 
five-coordinated by the N,N′,N′′-tridentate Schiff base ligand and two Br atoms in a distorted square-
pyramidal geometry. The three Zn-N bond lengths as apparent from (Table 1) are given as Zn(1)-N(1) 
2.243(3) Å, Zn(1)-N(2) 2.076(2) Å, Zn(1)-N(3) 2.331(2) Å, and two Zn-Br bond lengths are Zn(1)-Br(1) 
2.4036(4) (18) Å, Zn(1)-Br(2) 2.4172(4) Å. In the crystal, intermolecular C---H...Br hydrogen bonds 
link the adjacent molecules into infinite chains along the crystallographic axis. An intramolecular  
C---H...Br interaction is also observed. Table 2 summarizes the crystal data for compounds 8 and 9 
zinc(II) complexes. 
Table 1. Selected bond lengths [Ǻ] and Selected bond angles [°] for compounds 8 and 9. 
8          9          
Zn1 Br1 2.4036(4) Zn1 N1 2.1752(18) 
Zn1 Br2 2.4172(4) Zn1 N2 2.0752(18) 
Zn1 N1 2.243(3) Zn1 N3 2.217(2) 
Zn1 N2 2.076(2) Zn1 N4 1.9681(18) 
Zn1 N3 2.331(2) Zn1 N5 1.9698(19) 
 
8                                                                 9                                       
Br1 Zn1 Br2 116.905(15) N1 Zn1 N3 154.18(7) 
N1 Zn1 Br1 92.48(6) N2 Zn1 N1 75.30(7) 
N1 Zn1 Br2 95.00(6) N2 Zn1 N3 79.64(8) 
N1 Zn1 N3 151.50(8) N4 Zn1 N1 97.48(7) 
N2 Zn1 Br1 133.79(6) N4 Zn1 N2 133.47(8) 
N2 Zn1 Br2 108.28(6) N4 Zn1 N3 95.22(7) 
N2 Zn1 N1 73.92(9) N4 Zn1 N5 113.13(8) 
N2 Zn1 N3 79.37(9) N5 Zn1 N1 96.56(7) 
N3 Zn1 Br1 99.01(6) N5 Zn1 N2 113.35(8) 
N3 Zn1 Br2 102.71(5) N5 Zn1 N3 98.97(8) 
C1 N1 Zn1 128.0(2) C1 N1 Zn1 126.71(14) 
C5 N1 Zn1 113.25(18) C5 N1 Zn1 114.26(14) 
C6 N2 Zn1 120.85(19) C6 N2 Zn1 120.19(15) 
C8 N2 Zn1 115.86(19) C8 N2 Zn1 114.51(17) 
C9 N3 Zn1 100.28(17) C9 N3 Zn1 100.2(2) 
C13 N3 Zn1 115.48(17) C10 N3 Zn1 112.0(2) 
C6 N2 C8 122.7(2) C11 N3 Zn1 107.3(3) 
C8 N2 Zn1 115.86(19) C9' N3 Zn1 104.0(2) 
C9 N3 C13 109.5(2) C11 N3 Zn1 112.3(2) 
C1 N1 C5 118.7(3) C12 N4 Zn1 162.3(2) 
C10 N3 C13 107.5(2) C13 N5 Zn1 175.5(2) 
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Table 2. Crystal data for compounds 8 and 9. 
 8 9 
Empirical formula  C13H19Br2N3OZn  C13H17N5S2Zn  
Formula weight  458.50  372.81  
Temperature/K  100(2)  100(2)  
Crystal system  monoclinic  monoclinic  
Space group  P21/n  P21/n  
a/Å  9.8290(2)  13.7663(2)  
b/Å  14.0218(2)  9.4949(2)  
c/Å  12.1371(2)  13.8089(2)  
β/°  106.9180(10)  109.9460(10)  
Volume/Å3  1600.35(5)  1696.68(5)  
Z  4  4  
ρcalcmg/mm3  1.903  1.459  
m/mm−1  6.527  1.693  
F(000)  904  768  
Crystal size/mm3  0.33 × 0.25 × 0.11  0.35 × 0.31 × 0.19  
2Θ range for data collection  4.56 to 54°  5.14 to 54°  
Reflections collected  12535  15059  
Independent reflections  3496[R(int) = 0.0351]  3707[R(int) = 0.0232]  
Data/restraints/parameters  3496/0/182  3707/14/225  
Goodness-of-fit on F2  1.028  1.015  
Final R indexes [I >= 2σ (I)]  R1 = 0.0271, wR2 = 0.0595  R1 = 0.0296, wR2 = 0.0714  
Final R indexes [all data]  R1 = 0.0360, wR2 = 0.0624  R1 = 0.0402, wR2 = 0.0772  
Largest diff. peak/hole/e Å−3  0.679/−0.466  0.455/−0.428  
Compound 9 is a square-pyramidal zinc(II) complex in which the metal center is coordinated by  
the N,N′,N′′-tridentate Schiff base and the N atoms of two thiocyanate ligands (Figure 1). The 
CH2N(CH3)2 fragment is disordered over two sets of sites in a 0.529 (4):0.471 (4) ratio. Like the 
structure of the zinc(II) thiocyanate complexes of similar Schiff bases [42,43], the present structure is a 
mononuclear square-pyramidal metal complex, the τ value being 0.35. In contrast, the cadmium(II) 
thiocyanate complex of the same Schiff base [44], showed a polymeric structure wherein the metal 
centers are linked by the N:S-bridging thiocyanate ligands. In the crystal structure of the title 
compound, C---H...S interactions connect a pair of molecules, related by symmetry −x+1, −y, −z, 
around a center of inversion. The zinc atom is bonded to three donor nitrogen atoms of the ligand and 
two thiocyanates both bonded through the nitrogen atoms. The five Zn-N bond lengths as apparent 
from (Table 1) are given as Zn(1)-N(1) 2.1752(18) Å, Zn(1)-N(2) 2.0752(18) Å, Zn(1)-N(3) 2.217(2) Å, 
Zn(1)-N(4) 1.9681(18) Å, Zn(1)-N(5) 1.9698(19) Å. 
2.5. Antibacterial Activity Results 
A total of ten Schiff-bases compounds were synthesized and screened for potential antibacterial 
activity against the emerging multi-drug resistance nosocomial bacterial pathogens in hospital settings, 
namely, methicillin-resistant Staphylococcus aureus, A. baumanii, K. pneumonia and P. aeroginosa. In 
the first level antibacterial screening with the disc diffusion assay, all compounds under study were 
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tested against eight clinical strains, two from each bacterial species. Inhibition zones were observed in 
the Schiff base compounds. However, no inhibition zone was observed in any of the compounds tested 
against K. pneumonia (Table 3). All seven transition metal-bonded Schiff-base compounds were 
strongly inhibitive against MRSA, while they showed weak antibacterial activity against A. baumanii 
and P. aeroginosa in the disc diffusion test (Table 3). This higher antimicrobial activity of the metal 
complexes 4–10, compared with that of Schiff base ligands 1–3, is perhaps due to the change in 
structure as a result of coordination, as chelating tends to make metal complexes act as more  
powerful and potent bacteriostatic agents, thus inhibiting the growth of the microorganisms [45,46]. These 
seven compounds were then analyzed further for the MIC and MBC value using broth  
micro-dilution assay (Table 4). The result from broth micro-dilution assay was in total analogue to the 
disk diffusion screening. The test showed that, all of the seven compounds were most active against 
MRSA, with MIC value ranged from 0.7–2.9 µg/mL; MBC value ranged from 2.9–46.9 µg/mL  
(Table 4). Both A. baumanii and P. aeroginosa were resistant to the tested compounds at concentration 
lower than 93.8 and 187.0 µg/mL, respectively (Table 4). Therefore, it was concluded that these seven 
compounds were highly inhibitive only against the Gram positive bacterium MRSA. Further 
antibacterial tests were conducted against eight clinical strains of multi-drug resistant MRSA (Table 5) 
showing varying responses towards the seven selected Schiff-based compounds in the disc diffusion 
assay (Figure 2), however, they demonstrated twenty percent of resistance rate (two strains out of ten 
were resistant to the seven tested compounds). The broth micro-dilution assay resulted in similar 
findings, in which all, but MRSA 0807-1 and MRSA 0808-35, were inhibited at MIC ranging from 
“1.5 to 11.7” µg/mL. Both, MRSA 0807-1 and MRSA 0808-35, were only inhibited at MIC ranging 
from “209.7 to 419.4” µg/mL. (Table 6) presented the antibiogram of ten clinical strains of MRSA 
used in this antibacterial analysis with some known antibacterial drugs in which MRSA either showed 
resistant (R), susceptible (S) or intermediate resistant (I) towards them. 
Table 3. First level antibacterial screening Disc diffusion assay. 
Compound 
MRSA 
0804-25 
MRSA 
0807-7 
AC 
0612-7 
AC 
0903-21 
KB 
71 
KB 
83 
PA 
45 
PA 
104 
1 6 6 0 0 0 0 5 6 
2 5 5 0 0 0 0 5 5 
3 0 0 0 0 0 0 0 0 
4 21 22 7 7 0 0 8 8 
5 24 23 9 8 0 0 11 19 
6 22 23 9 8 0 0 10 10 
7 23 22 10 10 0 0 8 8 
8 21 20 10 9 0 0 9 9 
9 23 23 9 8 0 0 10 9 
10 22 22 7 7 0 0 10 9 
Control 
(DMSO) 
0 0 0 0 0 0 0 0 
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Table 4. Second level antibacterial screening. 
Minimum inhibitory concentration (MIC; µg/mL)/minimum bactericidal concentration (MBC; 
µg/mL) 
 
MRSA 
0804-25 
MRSA 
0807-7 
AC  
0612-7 
AC  
0903-21 
KB 71 KB 83 PA 45 PA 104 
1-3 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
4 0.7/2.9 1.5/2.9 93.8/750 93.8/750 375/750 375/750 187.5/750 187.5/750
5 0.7/2.9 0.7/2.9 93.8/750 93.8/750 187.5/750 187.5/750 187.5/750 187.5/750
6 1.5/5.9 1.5/5.9 93.8/375 93.8/375 375/750 375/750 187.5/750 187.5/750
7 1.5/5.9 1.5/5.9 93.8/375 93.8/375 187.5/750 187.5/750 187.5/750 187.5/750
8 1.5/5.9 1.5/2.9 93.8/750 93.8/750 375/750 375/750 187.5/750 187.5/750
9 1.5/5.9 1.5/23.4 187.5/750 187.5/750 375/750 375/750 187.5/750 187.5/750
10 2.9/46.9 2.9/46.9 187.5/750 187.5/750 375/750 375/750 187.5/750 187.5/750
DMSO 375/>375 375/>375 375/>375 375/>375 375/>375 375/>375 375/>375 375/>375 
n.d. = not determined. 
Table 5. Varying responses of the eight MRSA clinical strains towards the seven selected 
Schiff-base complexes in the disc diffusion assay. 
Compounds 
MRSA 
0805-21 
MRSA 
0806-1 
MRSA 
0807-1 
MRSA 
0807-19 
MRSA 
0808-35 
MRSA 
0809-15 
MRSA 
0809-25 
MRSA 
0809-38 
4 23 24 0 23 0 22 22 21 
5 23 24 0 25 0 23 23 23 
6 24 22 0 22 0 21 21 22 
7 24 20 0 21 0 19 20 20 
8 25 23 0 24 0 21 21 22 
9 23 23 0 22 0 23 24 23 
10 22 22 0 22 0 22 22 22 
(DMSO) 0 0 0 0 0 0 0 0 
Figure 2. Histogram for the 10 MRSA clinical strains of Schiff-base complexes. 
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Table 6. Antibiogram of the ten clinical strains of MRSA used in the antibacterial analysis. 
Strain No E CN LZD MUP RD DA TEC CIP NET TE VA FD OX SXT 
MRSA 0805-21 R R S S S S S R R R S S R R 
MRSA 0806-1 R R S S S S S R R R S S R R 
MRSA 0807-1 R R S S S S S R R R S S R R 
MRSA 0807-19 R R S S S S S R I S S S R S 
MRSA 0808-35 R R S S S S S I I R S S R R 
MRSA 0809-15 R R S S S S S R R R S S R R 
MRSA 0809-24 R R S S S S S R R R S S R R 
MRSA 0809-38 R R S S S S S R R R S S R S 
MRSA 0807-7 R R S S S S S R I R S S R R 
MRSA 0804-25 R R S S S S S R S S S S R S 
E = erythromycin; GN = gentamycin; LZD-linozolid acid; MUP = muciprocin; RD- rifampicin;  
DA = clindamycin; TEC = teicoplanin; CIP = ciproflozaxin; NET = netilmycin; TE = tetracycline;  
VA = vancomycin; FD = fusicidic acid; OX = oxacilin; SXT = Trimethoprim-sulfamethaxazole; R = resistant; 
S = sensitive; I = intermediate resistant. 
Figure 3. Photograph showing the antibacterial (MRSA 0804-25-A,B,C) and (MRSA 
0807-7-a,b,c) screening.  
 
3. Experimental  
General  
Melting points were determined using a MEL-TEMP II melting point instrument and were not 
corrected. Microanalyses were carried out on a Perkin-Elmer 2400 elemental analyzer. 1H-NMR and  
13C-NMR spectra were determined with a Lambda JEOL 400 MHz FT-NMR (1H: 400 MHz and 13C:  
100.4 MHz) spectrometer. Chemical shifts are given in δ values (ppm) using TMS as the internal 
standard. The IR spectra were taken with a Perkin-Elmer RX1 FT-IR spectrophotometer.  
2-Morpholino-N-(1-(pyridin-2-yl)ethylidene)ethanamine (1): A mixture of 4-(2-aminoethyl)-morpholine 
(0.65 g, 5 mmol) and 2-acetylpyridine (0.61 g, 5 mmol) in ethanol (50 mL) was refluxed for 2 h 
followed by addition of few drops of glacial acetic acid. The obtained orange oil was solidified upon 
standing for 12 h at 55 °C in an oven. 
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The solid product was recrystallized in methanol. Yield: 61.5%. Molecular formula: C13H19N3O. 
Analysis Calculated: C, 66.92; H, 8.21; N, 18.01. Found: C, 67.02; H, 8.52; N, 17.99. IR (ATR cm−1) 
2972.40 (C-H), 1690.00, 1642.08 (C=N), 1588.74, 1568.03 (C=N)pyr, 1450.89 (C-C), 1113.20 
(C-N), 1089.21 (O-C). UV-Vis (DMSO), 281.00 (n→π*); 224.00 (π→π*). 1H-NMR (DMSO-d6), 
8.69–7.95 (4H, CH-Ar), 3.79–3.837 (CH2-morph), 2.78–2.58 (NCH2-CH2N), 1.74 (CH3-). 13C-NMR 
(DMSO-d6). 164.53 [1C, δ(C=N)], 144.45 δ(C), 142.62 δ(CH), 136.40 δ(CH), 123.96 δ(CH), [5C, 
δ(Ar-pyr)], 61.23 [2C, δ(2CH2)], 52.08, 49.67 [2C, δ(2CH2)], 44.57 [C, δ(CH2)], 31.82 [2C, δ(CH2)], 
14.52 [C, δ(CH3)]. 
2-(Piperazin-1-yl)-N-(1-(pyridin-2-yl)ethylidene)ethanamine (2): A mixture of 4-(2-aminoethyl)-
piperazine (0.65 g, 5 mmol) and 2-acetylpyridine (0.61 g, 5 mmol) in ethanol (50 mL) was refluxed for 
three hours followed by addition of few drops of glacial acetic acid. 
 
The same procedure as for 1 was applied as the prototype in the isolation of other Schiff bases. 
Yield: 40.3%. Molecular formula: C13H20N4. Analysis Calculated: C, 67.21; H, 8.68; N, 24.12. Found: 
C, 68.19; H, 8.89; N, 24.48. IR (ATR cm−1) 3308.37 (N-H), 2945.30 (C-H), 1640.05 (C=N), 
1586.63 (C=N)pyr, 1464.94, 1436.55 (C-C), 1132.42 (C-N). UV-Vis (DMSO) 281.00 (n→π*); 
224.00 (π→π*). 1H-NMR (DMSO-d6) 8.30–7.85 (4H, CH-Ar), 3.98–3.69 (CH2-Pip.), 2.9 (NH-)  
2.75–2.55 (NCH2-CH2N), 1.21 (CH3-). 13C-NMR (DMSO-d6) 168.43 [1C, δ(C=N)], 148.47 δ(C), 
140.44 δ(CH), 127.93 δ(CH), 123.79 δ(CH), [5C, δ(Ar-pyr)], 51.72 [2C, δ(2CH2)], 44.19 [2C, 
δ(2CH2)], 42.04 [2C, δ(CH2)], 15.79 [1C, δ(CH3)]. 
N1,N1-Dimethyl-N2-(1-(pyridin-2-yl)ethylidene)ethane-1,2-diamine (3): An accurately measured 
amount of 2-acetylpyridine (0.61 g, 5 mmol) and N,N-dimethylethyldiamine (0.44 g, 5 mmol) in 
ethanol (25 mL) was refluxed for three hours. 
 
Yield: 54%. Molecular formula: C11H17N3 (191.27). Analysis Calculated: C, 69.87; H, 8.80; N, 13.58. 
Found: C, 68.48; H, 8.98; N, 14.98. IR (ATR cm−1) 2925.46 (C-H) 1639.70 (C=N) 1566.34 
(C=N)pyr, 1464.83, 1435.25 (C-C), 1153.71, 1103.38 (C-N). UV-Vis (DMSO) 321 (n→π*); 233 
(π→π*).1H-NMR (DMSO-d6) 8.28–7.87 (CH2-Ar), 2.76–2.68 (NCH2-CH2N), 1.22 (CH3-), 1.9 (6H, 
CH3-N). 13C-NMR (DMSO-d6) 166.59 [1C, δ(C=N)], 147.58 δ(C), 145.83 δ(CH), 139.56 δ(CH), 
126.82 δ(CH), [5C, δ(Ar-pyr)], 54.43 [2C, δ(2CH2)], 43.44. 43.29 [2C, δ(2CH3)], 14.69 [1C, δ(CH3)]. 
Aqua{Dithiocyanato-(2-morpholino-N-[1-(2-pyridylethylidene]ethanamine N,N',N''}cadmium(II) (4): A 
mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)morpholine (0.21 g, 1.65 mmol) 
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in ethanol (20 mL) was refluxed for 2 h followed by addition of a solution of cadmium(II) acetate 
dihydrate (0.44 g, 1.65 mmol) and sodium thiocyanate (0.268 g, 3.30 mmol) in a minimum amount of 
water. The mixture was refluxed for 2–3 h resulting in the formation of small amount of precipitate. 
More precipitate was obtained by removal of some solvent.  
 
The product was collected by filtration, washed several times with ethanol until a white colored 
compound is obtained. It was re-crystallized from the same solvent (ethanol), filtered to remove the 
suspended impurities. Yield = 75%. Melting point >400 °C. Analysis Calculated: [C, 39.09; H, 4.37; 
N, 18.23; S, 13.91]. Found: [C, 39.29; H, 4.17; N, 18.13; S, 13.61]. IR (ATR cm−1) 2981.09 (C-H), 
2157.91, 2083, (N=C=S), 1651.16 (C=N), 1438.25 (C-C), 1107.15 (C-N), 659.88 (OH2) 565.42 
(M-N). UV-Vis (DMSO) 407 (LMCT), 285 (n→π*); 234 (π→π*). 1H-NMR (DMSO-d6) 8.80 [s, 1H, 
δ(Ar-H)pyr], 8.29–8.24 [m, 2H, δ(Ar-H)pyr], 7.87–7.85 [t, 1H, δ(Ar-H)pyr], 3.80, 3.76 [d, 4H, 
δ(2CH2)], 3.69 [s, 4H, δ(2CH2)], 2.79–2.77 [t, 4H, δ(N-CH2)], 2.69 [s, 3H, δ(CH3)]. 13C-NMR 
(DMSO-d6) 165.80 [1C, δ(C=N)], 149.24 δ(C), 140.55 δ(CH), 132.31 δ(CH), 127.68 δ(CH), 124.29 
δ(CH) [5C, δ(Ar-pyr)], 64.76, 57.88 [4C, δ(2CH2) morph], 53.44, 44.36 [2C, δ(2CH2)], 21.98 
[δ(SCN)], 15.77 [1C, δ(CH3)]. 
Aqua{Dichlorido Piperazin-4-ium1-(2-pyridyl)ethylidene]ethanamine N,N′,N′′}cadmium (5): A 
mixture of 2-acetylpyridine (0.61 g, 5 mmol) and 4-(2-aminoethyl)piperazine (0.65 g, 5 mmol) in 
ethanol (50 mL) was refluxed for 2 h followed by addition of a solution of cadmium(II) chloride  
(0.92 g, 5 mmol) in a minimum amount of water was added. The mixture was refluxed for 2–3 h 
resulting in the formation of white precipitate. 
 
More precipitate was obtained by removal of some solvent. Analysis Calculated: C, 23.61; H, 3.55; 
N, 10.14. Found: C, 23.65; H, 3.75; N, 10.24. IR (ATR cm−1) 3469.07 (N-H), 2953.13 (C-H), 
1654.02 (C=N), 1438.11 (C-C), 1121.21 (C-N), 652.14 (OH2) 557.10 (M-N). UV-Vis (DMSO) 
497 (LMCT), 281 (n→π*); 229 (π→π*). 1H-NMR (DMSO-d6) 8.73–7.83 [m, 4H, δ(Ar-H)pyr], 3.92, 
3.81 [d, 4H, δ(2CH2)], 3.3–3.0 [t, 4H, δ(2CH2)], 2.82–2.80 [2H, δ(N-CH2)], 2.76 [2H, δ(NH-)],  
2.38–2.36 [t, 2H, δ(CH2=)], 2.30 [sbr, 1H, δ(NH)] 2.23 [s, 3H, δ(CH3)]. 13C-NMR (DMSO-d6) 166.938 
[1C, δ(C=N)], 157.942, 146.101, 137.967, 131.059, 124.085 [5C, δ(Ar-pyr)] 108.095, 106.975 
[δ(2CH2)], 69.65 [2C, δ(2CH2)], 40.67 [1C, δ(CH2)], 46.00 [1C, δ(CH2)], 18.95 [1C, δ(CH3)]. 
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Chlorido(2-{1-[(2-morpholinoethyl)imino]ethyl}phenolato N,N′,N′′)copper(II) (6): A mixture of  
2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl) morpholine (0.21 g, 1.65 mmol) in ethanol 
(20 mL) was refluxed. After 2 h a solution of copper (II) chloride dihydrate (0.28 g, 1.65 mmol) in a 
minimum amount of ethanol was added. The mixture was refluxed for 2–3 h resulting in the formation 
of a small precipitate. More precipitate was obtained by removal of some solvent. 
 
The product was collected by filtration, washed several times with ethanol until a green colored 
compound is obtained. It was re-crystallized from the same solvent (ethanol), filtered to remove the 
suspended impurities. Yield = 77%. Melting point 375–380 °C. Analysis Calculated: [C, 42.46; H, 
5.21; N, 11.43]. Found: [C, 42.19; H, 5.11; N, 11.39]. IR (ATR cm−1) 2949.37 (C-H), 1654.51 
(C=N), 1443.03 (C-C), 1144.39 (C-N), 577.38 (M-N). UV-Vis (DMSO) 645.50 (d→d*); 337.00 
(LMCT); 309.00 (n→π*); 223.00, 219.00 (π→π*). 
Dibromido{2-morpholino-N-[1-(2-pyridyl ethylidene ethanamine N,N′,N′′}cadmium (7): A mixture of 
4-(2-aminoethyl)morpholine (0.65 g, 5 mmol) and 2-acetylpyridine (0.61 g, 5 mmol) in ethanol  
(50 mL) was refluxed for 2 h followed by addition of a solution of cadmium(II) acetate dihydrate  
(0.44 g, 1.65 mmol) and potassium bromide (0.196 g, 1.65 mmol) in a minimum amount of water was 
added. The mixture was refluxed for 2–3 h resulting in the formation of a white precipitate. More 
precipitate was obtained by removal of some solvent. 
 
The product was collected by filtration, washed several times with ethanol until a white colored 
compound is obtained. It was re-crystallized from the same solvent (ethanol), filtered to remove the 
suspended impurities. Yield = 81%. Melting point >400 °C. Analysis Calculated: C, 37.48; H, 4.60;  
N, 10.09. Found: C, 37.28; H, 4.45; N, 10.19. IR (ATR cm−1) 296202 (C-H), 1650.04 (C=N), 
1458.80 (C-C), 1115.11 (C-N), 556.01 (M-N). UV-Vis (DMSO) 398 (LMCT), 279 (n→π*); 229 
(π→π*). 1H-NMR (DMSO-d6) 8.69–8.68 [d, 1H, δ(Ar-H)pyr], 8.29–8.24 [m, 2H, δ(Ar-H)pyr], 7.85  
[s, 1H, δ(Ar-H)pyr], 3.93, 3.80 [d, 4H, δ(2CH2)], 3.73–3.71 [t, 2H, δ(N-CH2)], 2.81, 2.80, 2.80, 2.72, 
2.70 [m, 6H, δ(3CH2) morph], 2.55 [s, 3H, δ(CH3)]. 13C-NMR (DMSO-d6) 166.90 [1C, δ(C=N)], 
149.13 δ(C), 147.64 δ(CH), 140.55 δ(CH), 127.72 δ(CH), 124.42 δ(CH), [5C, δ(Ar-pyr)], 64.65  
[2C, δ(2CH2)], 53.49 [2C, δ(2CH2)], 36.00 [1C, δ(CH2)], 30.67 [1C, δ(CH2)], 15.95 [1C, δ(CH3)]. 
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Dibromido {2-morpholino-N-[1-(2-pyridyl) ethylidene] ethanamine N,N′,N′′}zinc (8): A mixture of  
2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl) morpholine (0.21 g, 1.65 mmol) in ethanol 
(20 mL) was refluxed. After 2 h a solution of zinc (II) acetate dihydrate (0.36 g, 1.65 mmol) and 
potassium bromide (0.196 g, 1.65 mmol) in a minimum amount of water. The mixture was refluxed for 
2–3 h resulting in the formation of a small amount of precipitate. More precipitate was obtained by 
removal of some solvent. 
 
The product was collected by filtration, washed several times with ethanol until a milky colored 
compound is obtained. It was re-crystallized from the same solvent (ethanol), filtered to remove the 
suspended impurities and a single crystal was obtained suitable for x-ray analysis. Yield = 85%. 
Melting point >400 °C. Analysis Calculated: C, 30.89; H, 3.79; N, 8.31. Found: C, 30.79; H, 3.49; N, 
8.28. IR (ATR cm−1) 2959.01 (C-H), 1649.00 (C=N), 1439.00 (C-C), 1114.11 (C-N), 561.12 
(M-N). UV-Vis (DMSO) 498 (LMCT), 289 (n→π*); 229 (π→π*). 1H-NMR (DMSO-d6) 8.78, 8.77 
[d, 1H, δ(Ar-H)pyr], 8.30–8.25 [m, 2H, δ(Ar-H)pyr], 7.89–7.87 [t, 1H, δ(Ar-H)pyr], 3.89 [s, 4H, 
δ(2CH2)], 3.85–3.83 [t, 2H, δ(CH2)], 2.91–2.90 [t, 6H, δ(N-CH2)], 2.62 [s, 3H, δ(CH3)]. 13C-NMR 
(DMSO-d6) [1C, δ(C=N)], 168.38 δ(C), 146.49 δ(CH), 140.65 δ(CH), 128.03 δ(CH), 124.05 δ(CH) 
[5C, δ(Ar-pyr)], 62.88 [2C, δ(2CH2)], 54.55 [2C, δ(2CH2)], 52.09 [1C, δ(CH2)], 44.12 [1C, δ(CH2)], 
15.86 [1C, δ(CH3)]. 
N,N-Dimethyl-N'-[1-(2-pyridyl)ethylidene]ethane-1,2-diamine-3N,N′,N′′}bis(thiocyanate)zinc(II) (9): A 
mixture of 2-acetylpyridine (0.61 g, 5 mmol) and N,N-dimethylethyldiamine (0.44 g, 5 mmol) in 
ethanol (50 mL) was refluxed for 2 h followed by addition of a solution of Zinc (II) acetate (0.92 g,  
5 mmol) and sodium thiocyanate (0.406 g, 5 mmol) in a minimum amount of water. The mixture was 
refluxed for 2–3 h resulting in the formation of a white precipitate. More precipitate was obtained by 
removal of some solvent. 
 
The product was collected by filtration, washed several times with ethanol until a white colored 
compound is obtained. It was re-crystallized from the same solvent (ethanol), filtered to remove the 
suspended impurities. Yield = 72%. Melting point 370–375 °C. Analysis Calculated: C, 35.27; H, 
4.57; N, 11.22. Found: C, 35.17; H, 4.67; N, 11.21. IR (ATR cm−1) 2949.02 (C-H), 2070.00 
(N=C=S), 1655.03 (C=N), 1438.38 (C-C), 1139.09 (C-N), 477.06 (M-N). UV-Vis [λmax (nm) 
(DMSO)]. UV-Vis (DMSO) 497 (LMCT), 321 (n→π*); 233 (π→π*). 1H-NMR (DMSO-d6) 8.65, 8.64 
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[d, 1H, δ(Ar-H)pyr], 8.35–8.32 [m, 2H, δ(Ar-H)pyr], 7.95–7.94, 7.93 [m, 1H, δ(Ar-H)pyr], 3.79–3.77 
[t, 2H, δ(N-CH2)], 2.77–2.75 [t, 2H, δ(CH2=)], 2.59 [s, 3H, δ(CH3)], 2.39 [s, 6H, δ(2CH3)]. 13C-NMR 
(DMSO-d6) 168.74 [1C, δ(C=N)], 147.99 δ(C), 147.16 δ(CH), 141.36 δ(CH), 135.03 δ(CH), 128.50 
δ(CH) [5C, δ(Ar-pyr)], 56.35 [2C, δ(2CH3)], 44.55 [1C, δ(N-CH2)], 44.32 [1C, δ(CH2=)], 22.75 
[δ(SCN)], 15.88 [1C, δ(CH3)]. 
Aqua {2-morpholino-N-[1-(2-pyridyl)ethylidene] ethanamine N,N′,N′′}bis(thiocyanato) nickel(II) (10): A 
mixture of 2-acetylpyridine (0.20 g, 1.65 mmol) and 4-(2-aminoethyl)morpholine(0.21 g, 1.65 mmol) 
in ethanol (20 mL) was refluxed for 2 h followed by addition of a solution of nickel(II) acetate 
tetrahydrate (0.41 g, 1.65 mmol) and sodium thiocyanate (0.134 g, 1.65 mmol) in a minimum amount 
of water. The mixture was refluxed for 2–3 h resulting in the formation of a greenish colored 
precipitate. More precipitate was obtained by removal of some solvent. 
 
The product was collected by filtration, washed several times with ethanol until a green colored 
compound is obtained. It was re-crystallized from the same solvent (ethanol), filtered to remove the 
suspended impurities. Yield = 68%. Melting point 365–370 °C. Analytical Calculated: C, 42.27; H, 
4.97; N, 16.43; S, 15.05. Found: C, 42.31; H, 4.98; N, 16.43; S, 15.09. IR (ATR cm−1) 2980.11  
(C-H), 2082.19 (N=C=S), 1651.60 (C=N), 1441.21 (C-C), 1106.78 (C-N), 659.16 (OH2) 
515.83 (M-N), 461.51 (M-O). UV-Vis (DMSO) 745.00 (d→d*); 574.00 (LMCT); 279.00 (π→π*). 
3.1. X-Ray Structure Analyses 
A single crystal of the complexes suitable for X-ray diffraction were mounted on a glass fibre using 
perfluoropolyether oil and cooled rapidly to 100 K in a stream of cold N2. Diffraction data were 
measured using a Bruker APEX II CCD area-detector diffractometer (graphite monochromated Mo Ka 
radiation, λ = 0.71073 Å). The orientation matrix, unit cell refinement and data reduction were all 
handled by the APEX II software (SAINT integration, SADABS absorption correction [47]. The 
structure was solved using direct methods and vectors in the program SHELXS-97 [48] and was 
refined by the full matrix least-squares method on F2 with SHELXL-97 [48]. All the nonhydrogen 
atoms were refined anisotropically and all the hydrogen atoms were placed at calculated positions and 
refined isotropically. Drawings of the molecules were produced with XSEED [49].  
4. Pharmacology 
4.1. Bacterial Strains 
The antibacterial activities of the investigated compounds were tested against a panel of multi-drug 
resistant nosocomial bacterial pathogens, consisted of ten (10) isolates of methicillin-resistant 
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Staphylococcus aureus (MRSA)–MRSA 0804-25, MRSA 0805-21, MRSA 0806-1, MRSA 0807-1, MRSA 
0807-7, MRSA 0807-19, MRSA 0808-35, MRSA 0809-15, MRSA 0809-24, MRSA 0809-38; two (2) 
isolates of Acinetobacter baumannii(AC)–AC 0612-7, AC 0903-21, two (2) isolates of Klebsiella 
pneumonia (KB)–KB 71, KB 83, and two (2) isolates of Pseudomonas aeruginosa (PA)–P. aeruginosa. 
All tested bacterial strains of MRSA were of clinical origin and have shown resistance to at least four 
antibiotics (Table 6). For each bacterial species, six to ten strains were included in the antibacterial 
study to capture possible drug resistance variation within species. All bacterial strains used in this 
study were obtained from the bacteria culture collection of Biomedical Science Laboratory, Institute of 
Graduate Studies University of Malaya, Kuala Lumpur, Malaysia.  
4.1.1. Antimicrobial Testing 
The synthesized compounds were first screened for potential antibacterial activity by testing against 
two randomly selected strains from each bacterial species, using disc diffusion assay [50]. Briefly, a 
loopful of an overnight bacterial culture of each strain was suspended in sterile 0.85% saline (BDH) to 
the concentration of approximately 108 cfu/mL (equivalent to 0.5 Mc Farland units) before inoculated 
evenly on the entire surface of Mueller Hinton agar (Oxoid) with a sterile cotton swab. Sterilized  
paper discs (Thermo Fisher, 6 mm diameter), impregnated with 30 µg of respective synthetic Schiff 
compound, and was placed on the inoculated agar plate. DMSO disc was used as a negative control  
in the test. The diameter of inhibition zone around the impregnated paper disc was measured after  
18 h of incubation at 37 °C. All tests were performed in duplicate. Synthetic Schiff base compounds, in 
which inhibition zone was observed in any one of the four species tested, were selected for MIC and 
MBC determination with broth micro-dilution assay. Only compounds with MIC and MBC value 
lesser than “10 µg/mL” is considered potentially active against the corresponded bacterial species; and 
further tested against the entire collection of the corresponded bacterial species with disc diffusion 
assay. This was to determine the variation in the susceptibility responses to the tested compound 
within the bacterial species tested. The two selected strains for each species in the initial screening 
were: MRSA 0804-25 and MRSA 0807-7 for MRSA (Figure 3); AC 0612-7 and AC 0903-21 for A. 
baumannii; KB 71 and KB 83 for K. pneumonia; and PA45 and PA104 for P. aeruginosa.  
4.1.2. MIC Determination 
Minimum inhibition concentrations (MICs) were determined with a 96-well broth micro-dilution 
assay. The inoculum was prepared by suspending an overnight culture in a sterile 0.85% saline (BDH) 
to approximate 108 cfu/mL (equivalent to 0.5 McFarland units) and further diluted in cation adjusted 
Mueller Hinton broth (CMHB; BD) to the concentration of 106 cfu/mL. Two-fold serial dilutions of 
the tested compound were prepared in CMHB across the 96-well microtiter plate with the highest 
concentration starting from 750 ppm (750 µL/mL) in duplicate rows. The prepared suspension of the 
bacteria was added to each well except the negative control wells of the microtitre plate in a 1:1 ratio 
with final bacteria concentration of approximately “5 × 105” cfu/mL. The inoculated microtitre plates 
were incubated at 37 °C for 24 h. The MIC was determined as the lowest concentration of the test 
compound that exhibits no visible growth. A further confirmative test was done by adding 30 µL of 
MTT dye (Sigma) to each well. Wells with color changes within 30–60 min incubation at room 
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temperature were scored as positive growth. The lowest concentration of the tested compound that 
exhibits no color changes (yellow) is determined as the MIC value.  
4.1.3. MBC Determination 
The MBC, minimal bactericidal concentration was tested by sub culturing 100 µL from each well of 
the incubated plate into Mueller Hinton Agar. The MBC was determined as the lowest concentration of 
the test compound that exhibits no viable microorganism growth on the Mueller Hinton Agar plate. 
The antimicrobial compound is regarded as bactericidal if the MBC is not more than four times the MIC.  
5. Conclusions  
In conclusion, Schiff-based complexes were highly inhibitive only against the Gram positive 
bacterium MRSA, and as such could be potential antibacterial drugs to control MRSA nosocomial 
infections in hospital settings.  
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